Insights

Strategic Acquisition Opportunity Orna Therapeutics is at an advanced stage with a strong in vivo circular RNA platform (oRNA) and LNP delivery, recently tied to a potential up to $2.4B cash deal with Lilly. This signals readiness for significant corporate partnerships or licensing of core technologies to scale clinical programs and explore co-development with large pharma.

In Vivo CAR Growth Recent ASH data highlighting preclinical in vivo CAR programs for autoimmune and oncology applications suggests demand for collaborators or buyers of their in vivo cell therapy capabilities, including targeting B cell mediated diseases and plasma cell/BCMA-related pathways.

BCMA and CD19 Focus Strategic emphasis on BCMA and CD19 targets through circular RNA and CAR modalities presents clear near-term opportunities with hematology and oncology developers seeking innovative tools for multiple myeloma and B cell driven diseases.

Global Collaborations Active and expanding collaborations, notably with Shanghai Simnova and memory of exclusive rights in Greater China, indicate openness to regional partnerships and cross-border licensing, ideal for BD outreach to expand geographic reach or co-development deals.

Scale and Funding Readiness Revenue tier and substantial funding position Orna as a credible partner for late-stage manufacturing, regulatory support, and milestone-driven collaboration, appealing to sponsors seeking risk-sharing development programs and scalable RNA delivery solutions.

Similar companies to Orna Therapeutics

Orna Therapeutics Tech Stack

Orna Therapeutics uses 8 technology products and services including NetSuite, Shopify, Mimecast, and more. Explore Orna Therapeutics's tech stack below.

Media & News

Orna Therapeutics's Email Address Formats

Orna Therapeutics uses at least 3 email formats:
Orna Therapeutics Email FormatsExamplePercentage
FLast@ornatx.comJDoe@ornatx.com
89%
First.Last@ornatx.comJohn.Doe@ornatx.com
10%
FL@ornatx.comJD@ornatx.com
1%

Frequently Asked Questions

What is Orna Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Orna Therapeutics's official website is ornatx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Orna Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Orna Therapeutics's annual revenue is estimated to be $50M - $100M.

What is Orna Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Orna Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Orna Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Orna Therapeutics has approximately 108 employees across 4 continents, including North America, Europe and Africa. Key team members include Ceo: S. D., Business Development Founder & Director: R. S. and Preclinical Research Co-Op: M. A. M. Explore Orna Therapeutics's employee directory with LeadIQ.

What industry does Orna Therapeutics belong to?

Minus sign iconPlus sign icon
Orna Therapeutics operates in the Biotechnology Research industry.

What technology does Orna Therapeutics use?

Minus sign iconPlus sign icon
Orna Therapeutics's tech stack includes NetSuite, Shopify, Mimecast, Google Cloud, DocuSign, Office 365, WP Engine and Smartsheet.

What is Orna Therapeutics's email format?

Minus sign iconPlus sign icon
Orna Therapeutics's email format typically follows the pattern of FLast@ornatx.com. Find more Orna Therapeutics email formats with LeadIQ.

How much funding has Orna Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Orna Therapeutics has raised $321M in funding. The last funding round occurred on Aug 16, 2022 for $221M.

When was Orna Therapeutics founded?

Minus sign iconPlus sign icon
Orna Therapeutics was founded in 2019.
Orna Therapeutics logo

Orna Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Orna Therapeutics is a mid-sized biotechnology company based in Watertown, Massachusetts. It is advancing RNA-based therapies by developing a circular RNA platform, known as oRNA, alongside new lipid nanoparticle delivery approaches to enable in vivo treatments for disease. The aim is to broaden the therapeutic potential of circular RNA and to support the development of safe, effective in vivo therapies.

In late 2025, the company reported preclinical data for its in vivo CAR programs targeting B cell–driven autoimmune diseases and BCMA-related conditions, presented at the ASH annual meeting. More recently, Orna disclosed the development of ORN-252, a program directed at the CD19 lymphocyte surface antigen for treating autoimmune diseases driven by B cells. These developments illustrate a concentrated effort on autoimmune indications and immune-cell–targeted approaches within its research portfolio.

Section iconCompany Overview

Website
ornatx.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
51-200

Section iconFunding & Financials

  • $321M

    Orna Therapeutics has raised a total of $321M of funding over 3 rounds. Their latest funding round was raised on Aug 16, 2022 in the amount of $221M as a Series B.

  • $50M - $100M

    Orna Therapeutics's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.